Background Estrogen and androgen have been linked to the regulation of circulating hepatocyte growth factor (HGF), an adipose tissue-derived cytokine. It is possible that the CYP19A1 gene which alters sex hormones production may influence HGF levels. We examined the association between the CYP19A1 gene variants and plasma HGF concentrations. Design We evaluated 45 common and putative functional variants of CYP19A1 and circulating levels of HGF among 260 postmenopausal women who later developed colorectal cancer from the Women's Health Initiative Observational Cohort. As the distribution of HGF levels was highly skewed, we transformed HGF concentrations for all women into a log-, ranked-, or normal score-scale value. Multiple linear regression with adjustment for age was used to evaluate the associations. Results We observed an association between the rs7172156, rs1008805, rs6493494, rs749292, and rs11636639 variants and HGF levels in ranked and normal score scales (corrected p values ≤0.02), although the association of these 5 SNPs with log-scale HGF was not significant (corrected p values ≥0.16). The associations remained unchanged after additional adjustment for hormone therapy use and estradiol levels. These 5 SNPs, which were in linkage disequilibrium (pairwise D′≥97%, r2≥56%), constituted a block with 2 common haplotypes accounting for 82% frequency. The most common haplotype, TCCCA, was associated with lower ranked- or normal score-transformed HGF levels (corrected p values ≤0.001), whereas the second most common haplotype, CTTCA, was associated with higher ranked- or normal score-transformed HGF levels (corrected p values ≤0.02). Conclusion Our findings of a potential association between the CYP19A1 variants and circulating HGF levels warrant confirmation in studies with larger sample size.
References
[1]
Subbaramaiah K, Howe LR, Bhardwaj P, Du B, Gravaghi C, et al. (2011) Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. Cancer Prev Res (Phila) 4: 329–346.
[2]
Hursting SD, Nunez NP, Varticovski L, Vinson C (2007) The obesity-cancer link: lessons learned from a fatless mouse. Cancer Res 67: 2391–2393.
[3]
Ronti T, Lupattelli G, Mannarino E (2006) The endocrine function of adipose tissue: an update. Clin Endocrinol (Oxf) 64: 355–365.
[4]
Rehman J, Considine RV, Bovenkerk JE, Li J, Slavens CA, et al. (2003) Obesity is associated with increased levels of circulating hepatocyte growth factor. J Am Coll Cardiol 41: 1408–1413.
[5]
Hayashi Y, Saitoh S, Takagi S, Tuchihashi K, Miura T, et al. (2002) Hepatocyte growth factor and 24-hour ambulatory blood pressure monitoring. Hypertens Res 25: 655–660.
[6]
Hiratsuka A, Adachi H, Fujiura Y, Yamagishi S, Hirai Y, et al. (2005) Strong association between serum hepatocyte growth factor and metabolic syndrome. J Clin Endocrinol Metab 90: 2927–2931.
[7]
Rajpathak SN, Wang T, Wassertheil-Smoller S, Strickler HD, Kaplan RC, et al. (2010) Hepatocyte growth factor and the risk of ischemic stroke developing among postmenopausal women: results from the Women's Health Initiative. Stroke 41: 857–862.
[8]
Morishita R, Aoki M, Yo Y, Ogihara T (2002) Hepatocyte growth factor as cardiovascular hormone: role of HGF in the pathogenesis of cardiovascular disease. Endocr J 49: 273–284.
[9]
Zhang X (2010) Hepatocyte growth factor system in the mouse uterus: variation across the estrous cycle and regulation by 17-beta-estradiol and progesterone. Biol Reprod 82: 1037–1048.
[10]
Coleman KD, Ghosh M, Crist SG, Wright JA, Rossoll RM, et al. (2012) Modulation of hepatocyte growth factor secretion in human female reproductive tract stromal fibroblasts by poly (I:C) and estradiol. Am J Reprod Immunol 67: 44–53.
[11]
Tam NN, Chung SS, Lee DT, Wong YC (2000) Aberrant expression of hepatocyte growth factor and its receptor, c-Met, during sex hormone-induced prostatic carcinogenesis in the Noble rat. Carcinogenesis 21: 2183–2191.
[12]
Baruscotti I, Barchiesi F, Jackson EK, Imthurn B, Stiller R, et al. (2010) Estradiol stimulates capillary formation by human endothelial progenitor cells: role of estrogen receptor-{alpha}/{beta}, heme oxygenase 1, and tyrosine kinase. Hypertension 56: 397–404.
[13]
Dudkowska M, Stachurska A, Chmurzyska W, Grzelakowska-Sztabert B, Manteuffel-Cymborowska M (2001) Cross-talk between steroid-receptor-mediated and cell-membrane-receptor-mediated signalling pathways results in the in vivo modulation of c-Met and ornithine decarboxylase gene expression in mouse kidney. Biochem J 353: 317–323.
[14]
Means GD, Mahendroo MS, Corbin CJ, Mathis JM, Powell FE, et al. (1989) Structural analysis of the gene encoding human aromatase cytochrome P-450, the enzyme responsible for estrogen biosynthesis. J Biol Chem 264: 19385–19391.
[15]
Wake DJ, Strand M, Rask E, Westerbacka J, Livingstone DE, et al. (2007) Intra-adipose sex steroid metabolism and body fat distribution in idiopathic human obesity. Clin Endocrinol (Oxf) 66: 440–446.
[16]
Vistoropsky Y, Trofimov S, Malkin I, Kobyliansky E, Livshits G (2008) Genetic and environmental determinants of hepatocyte growth factor levels and their association with obesity and blood pressure. Ann Hum Biol 35: 93–103.
[17]
Burdon KP, Macgregor S, Bykhovskaya Y, Javadiyan S, Li X, et al. (2011) Association of polymorphisms in the hepatocyte growth factor gene promoter with keratoconus. Invest Ophthalmol Vis Sci 52: 8514–8519.
[18]
Naim R, Braun T, Sauter A, Barnes J, Aust W, et al. (2008) VCAM-1 increases levels of HGF in eosinophilic chronic rhinosinusitis cell culture. In Vivo 22: 77–81.
[19]
Simpson ER (2000) Role of aromatase in sex steroid action. J Mol Endocrinol 25: 149–156.
[20]
Mendelson CR, Jiang B, Shelton JM, Richardson JA, Hinshelwood MM (2005) Transcriptional regulation of aromatase in placenta and ovary. J Steroid Biochem Mol Biol 95: 25–33.
[21]
Haiman CA, Dossus L, Setiawan VW, Stram DO, Dunning AM, et al. (2007) Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women. Cancer Res 67: 1893–1897.
[22]
Beckmann L, Husing A, Setiawan VW, Amiano P, Clavel-Chapelon F, et al. (2010) Comprehensive analysis of hormone and genetic variation in 36 genes related to steroid hormone metabolism in pre- and postmenopausal women from the breast and prostate cancer cohort consortium (BPC3). J Clin Endocrinol Metab 96: E360–367.
[23]
Petry CJ, Ong KK, Michelmore KF, Artigas S, Wingate DL, et al. (2006) Associations between common variation in the aromatase gene promoter region and testosterone concentrations in two young female populations. J Steroid Biochem Mol Biol 98: 199–206.
[24]
Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, et al. (2008) Insulin, insulin-like growth factor-I, endogenous estradiol, and risk of colorectal cancer in postmenopausal women. Cancer Res 68: 329–337.
[25]
Riancho JA, Valero C, Naranjo A, Morales DJ, Sanudo C, et al. (2007) Identification of an aromatase haplotype that is associated with gene expression and postmenopausal osteoporosis. J Clin Endocrinol Metab 92: 660–665.
[26]
Goodman MT, Lurie G, Thompson PJ, McDuffie KE, Carney ME (2008) Association of two common single-nucleotide polymorphisms in the CYP19A1 locus and ovarian cancer risk. Endocr Relat Cancer 15: 1055–1060.
[27]
Setiawan VW, Doherty JA, Shu XO, Akbari MR, Chen C, et al. (2009) Two estrogen-related variants in CYP19A1 and endometrial cancer risk: a pooled analysis in the Epidemiology of Endometrial Cancer Consortium. Cancer Epidemiol Biomarkers Prev 18: 242–247.
[28]
Sheen-Chen SM, Liu YW, Eng HL, Chou FF (2005) Serum levels of hepatocyte growth factor in patients with breast cancer. Cancer Epidemiol Biomarkers Prev 14: 715–717.
[29]
Gupta A, Karakiewicz PI, Roehrborn CG, Lotan Y, Zlotta AR, et al. (2008) Predictive value of plasma hepatocyte growth factor/scatter factor levels in patients with clinically localized prostate cancer. Clin Cancer Res 14: 7385–7390.
[30]
Toiyama Y, Miki C, Inoue Y, Okugawa Y, Tanaka K, et al. (2009) Serum hepatocyte growth factor as a prognostic marker for stage II or III colorectal cancer patients. Int J Cancer 125: 1657–1662.
[31]
Cai H, Shu XO, Egan KM, Cai Q, Long JR, et al. (2008) Association of genetic polymorphisms in CYP19A1 and blood levels of sex hormones among postmenopausal Chinese women. Pharmacogenet Genomics 18: 657–664.
[32]
Lin JH, Manson JE, Kraft P, Cochrane BB, Gunter MJ, et al. (2011) Estrogen and progesterone-related gene variants and colorectal cancer risk in women. BMC Med Genet 12: 78.
[33]
Ho GY, Wang T, Gunter MJ, Strickler HD, Cushman M, et al. (2012) Adipokines Linking Obesity with Colorectal Cancer Risk in Postmenopausal Women. Cancer Res 72: 3029–3037.
[34]
The Women's Health Initiative Study Group (1998) Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Control Clin Trials 19: 61–109.
[35]
Kaplan RC, Ho GY, Xue X, Rajpathak S, Cushman M, et al. (2007) Within-individual stability of obesity-related biomarkers among women. Cancer Epidemiol Biomarkers Prev 16: 1291–1293.
[36]
Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21: 263–265.
[37]
Otsuka M, Adachi H, Jacobs DR Jr, Hirai Y, Enomoto M, et al. (2012) Serum Hepatocyte Growth Factor and Cancer Mortality in an Apparently Healthy Japanese Population. J Epidemiol.
[38]
Rajpathak SN, Wassertheil-Smoller S, Crandall J, Liu S, Ho GY (2010) Hepatocyte growth factor and clinical diabetes in postmenopausal women. Diabetes Care 33: 2013–2015.
[39]
Rajpathak SN, Wang T, Wassertheil-Smoller S, Strickler HD, Kaplan RC, et al. (2010) Hepatocyte growth factor and the risk of ischemic stroke developing among postmenopausal women: results from the Women's Health Initiative. Stroke 41: 857–862.
[40]
Woodward M (2005) Epidemiology: Study design and data analysis. New York: Chapman and Hall/CRC.
[41]
Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81: 559–575.
